biotech · Metastatic Non-Small Cell Lung Cancer · NSCLC · AVBP
ArriVent BioPharma
ArriVent BioPharma is a biotech organization headquartered in Newtown Square, USA. It trades on NYSE under ticker AVBP. Primary therapeutic focus areas include Metastatic Non-Small Cell Lung Cancer, NSCLC, Non-Small-Cell
Newtown Square, USA HQ
75 Employees
Public company Type
AVBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Newtown Square, USA
- Employees
- 75
- Programs
- 7
- Drugs
- 4
- Patents
- 0
Furmonertinib
Phase 1 · small molecule · Non-Small Cell Lung Cancer (NSCLC)
Furmonertinib for Non-Small Cell Lung Cancer (NSCLC) is a Phase 1 program (small_molecule) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Internal code FURMO-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ArriVent BioPharma
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Non-Small Cell Lung Cancer (NSCLC)
- Status
- active
- Trials
- 1